DNAe, the inventors of semiconductor-based next-generation sequencing (NGS) technology, are developing a revolutionary new platform that enables NGS-based diagnostic capability in an easy to use, cartridge-based system. This system will deliver clinically relevant, actionable results directly from clinical specimens in a matter of hours.
DNAe semiconductor technology generates vast amounts of raw data which needs to be preprocesses in real time and the analysed using machine rearnich algorithms in semi-real-time fashion.
Regius Professor Chris Toumazou FRS, FREng, FMedSci founded the company in 2003, as a spin-out from Imperial College, London, having invented a way of detecting protons released during DNA synthesis to enable DNA sequence detection using a standard silicon-chip based transistor. This optics-free, label-free method shifted DNA sequencing from specialized, expensive genome centres into the mainstream of local labs and primary care clinics.
Our company has grown to encompass the vast range of disciplines required to build molecular interfaces and assays on a semiconductor platform. Our core competencies in electronic engineering, molecular biology, fluidics and chemistry make us a force to be reckoned with. A force for good.
Headquartered in London, UK, and operating from Washington, DC, our company has expanded operations further in 2015 with a clinical diagnostic development and manufacturing site in San Diego, CA.